Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

RedHill Biopharma ($RDHL) stock perked up as the company announced starting two GI-focused products in the U.S. These products are Donnatal, to be used for the adjunctive treatment of irritable bowel syndrome and EnteraGam, designed for the dietary management of chronic diarrhea and loose stools. The company has inked an exclusive co-promotion agreement with Concordia International for Donnatal. The agreement allows for the revenue sharing between the companies. It has also exclusively licensed EnteraGam from Entera Health. The company will pay royalties on net sales.
RedHill stock is currently 9 percent down on YTD basis. The company is focused on the development and commercialization of clinical-stage, orally-administered, small molecule drugs.

Aptose Biosciences ($APTO) stock is on rally as the company announced updates for its pipeline candidates CG'806 and APTO-253. The company plans to continue with its study of APTO-253, a c-Myc oncogene inhibitor. The company aims to find the root cause of recent manufacturing setbacks related to the intravenous formulation, it also plans to restore the molecule to an appropriate state for clinical trials and partnering. CG’806 is a pan-FLT3/BTK inhibitor, showed superiority over other agents in a cellular model of FLT3-positive AML. It successfully eliminated AML FLT3-ITD tumors without toxicity in a mouse model.
The company stock gained over 21 percent in its previous trading session, taking its YTD gain to 12.23 percent. The stock is down 47 percent on 12 months basis.

 

Endo International ($ENDP) President & CEO Paul Campanelli said the company will work with the FDA over the issue of OPANA ER availability. He claimed that OPANA ER is prescribed nearly 50,000 times each month. He also added that the company will no longer promote pain products.
Bristol-Myers Squibb ($BMY) announced voluntarily recalling a single lot of blood thinner Eliquis (apixaban) that was distributed to wholesalers and retail pharmacies in February.  The decision has been taken pursuant to a complaint that a bottle labeled as 5 mg tablets was found to contain 2.5 mg tablets.

Pfizer ($PFE) announced that its  Phase 3-stage tanezumab has been designated for Fast Track review by the FDA for the treatment of chronic pain in patients with osteoarthritis and chronic back pain. The company is collaborating with Eli Lilly for this purpose.
NeuroMetrix ($NURO) announced that it has been issued U.S. Patent No. 9,675,801 by the USPTO covering novel mechanisms to help Quell users safely obtain pain relief therapy over extended periods of time

 

Pulmatrix ($PULM) announced inking a new deal with Janssen Biotech subsidiary RespiVert Ltd. for exclusive global rights to a portfolio of kinase inhibitors that it intends to develop for inhaled formulations based on its iSPERSE technology. The companies did not disclose the financial terms of the contract.

AbbVie ($ABBV) announced inking a collaboration with privately held Principia Biopharma for developing oral immunoproteasome inhibitors for the potential treatment of autoimmune and inflammatory disorders. AbbVie will be responsible for ongoing clinical development and commercialization of compounds resulting from the partnership.

Brokerage
Action
Company
Rating
Price Target
Impact on Share Price
Royal Bank Of Canada
Reiterates
Almost Family (AFAM)
Buy
$63.00
Low
Leerink Swann
Downgrades
Alkermes PLC (ALKS)
Outperform -> Market Perform
$68.00 -> $61.00
Medium
Oppenheimer Holdings
Set Price Target
Amgen (AMGN)
Buy
$189.00
Low
Morgan Stanley
Raises Target
Amgen (AMGN)
Overweight
$183.00 -> $184.00
Low
Cantor Fitzgerald
Downgrades
athenahealth (ATHN)
Overweight -> Neutral
$140.00
Low
Cowen and Company
Reiterates
Axovant Sciences (AXON)
Outperform
$22.00 -> $30.00
Low
Maxim Group
Set Price Target
Brainstorm Cell Therapeutics (BCLI)
Buy
$8.00
Low

Gainers (% price change)Last TradeChangeMkt CapOmeros CorporationOMER19.58+2.48 (14.50%)962.18MAcelRx PharmaceuticalsACRX2.38+0.17 (7.95%)106.57MBioTime, Inc.BTX3.38+0.22 (6.96%)371.24MAntares Pharma IncATRS2.97+0.19 (6.83%)454.92MImmunoGen, Inc.IMGN4.64+0.28 (6.42%)411.74MLosers (% price change)GTx, Inc.GTXI4.82-1.33 (-21.63%)153.89MGenMark Diagnostics, IncGNMK11.82-1.03 (-8.02%)559.18MLeMaitre Vascular IncLMAT27.90-1.61 (-5.46%)500.69MImmunomedics, Inc.IMMU7.50-0.35 (-4.46%)788.79MMediciNova, Inc.MNOV5.50-0.25 (-4.35%)190.64MMost Actives (dollar volume)Johnson & JohnsonJNJ132.02+0.20 (0.15%)356.42BMerck & Co., Inc.MRK63.27-0.65 (-1.02%)173.05BPfizer Inc.PFE32.58-0.12 (-0.37%)193.60BGilead Sciences, Inc.GILD65.15-0.28 (-0.43%)86.09BUnitedHealth Group IncUNH181.05+1.80 (1.00%)172.35B